https://orcid.org/0000-0002-8276-0411
References
- Gong Z, Wang W, Hu S. Cytogenetic alterations in CML: not all created equal. Oncotarget. 2018;9:11885–11886. doi:https://doi.org/10.18632/oncotarget.24471.
- Houshmand M, Simonetti G, Circosta P, et al. Chronic myeloid leukemia stem cells. Leukemia. 2019;33:1543–1556. doi:https://doi.org/10.1038/s41375-019-0490-0.
- Jain S, Abraham A. BCR-ABL1-like B-acute lymphoblastic leukemia/lymphoma: A comprehensive review. Arch Pathol Lab Med. 2020;144:150–155. doi:https://doi.org/10.5858/arpa.2019-0194-RA.
- Valent P, Hadzijusufovic E, Hoermann G, et al. Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. Leuk Res. 2017;59:47–54. doi:https://doi.org/10.1016/j.leukres.2017.05.008.
- Copland M. Is there a role for dose modification of TKI therapy in CML? Curr Hematol Malig Rep. 2019;14:337–345. doi:https://doi.org/10.1007/s11899-019-00524-w.
- Jung SY, Kim OB, Kang HK, et al. Protein kinase Cα/β inhibitor Gö6976 promotes PC12 cell adhesion and spreading through membrane recruitment and activation of protein kinase Cδ. Exp Cell Res. 2013;319:153–160. doi:https://doi.org/10.1016/j.yexcr.2012.10.003.
- Yoon TW, Kim YI, Cho H, et al. Ameliorating effects of Gö6976, a pharmacological agent that inhibits protein kinase D, on collagen-induced arthritis. PloS One. 2019;14:e0226145.
- Merzoug-Larabi M, Spasojevic C, Eymard M, et al. Protein kinase C inhibitor Gö6976 but not Gö6983 induces the reversion of E- to N-cadherin switch and metastatic phenotype in melanoma: identification of the role of protein kinase D1. BMC Cancer. 2017;17:12. doi:https://doi.org/10.1186/s12885-016-3007-5.
- Feng Z, Xu S, Liu M, et al. Chk1 inhibitor Gö6976 enhances the sensitivity of nasopharyngeal carcinoma cells to radiotherapy and chemotherapy in vitro and in vivo. Cancer Lett. 2010;297:190–197. doi:https://doi.org/10.1016/j.canlet.2010.05.011.
- Yao J, Zhao X, Ding X. Systematic profiling of chemotherapeutic drug response to EGFR gatekeeper mutation in non-small cell lung cancer. Comput Biol Chem. 2016;64:126–133. doi:https://doi.org/10.1016/j.compbiolchem.2016.05.009.
- Yoshida A, Ookura M, Zokumasu K, et al. Gö6976, a FLT3 kinase inhibitor, exerts potent cytotoxic activity against acute leukemia via inhibition of survivin and MCL-1. Biochem Pharmacol. 2014;90:16–24. doi:https://doi.org/10.1016/j.bcp.2014.04.002.
- Grandage VL, Everington T, Linch DC, et al. Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells. Br J Haematol. 2006;135:303–316. doi:https://doi.org/10.1111/j.1365-2141.2006.06291.x.
- Gupta P, Zhang GN, Barbuti AM, et al. Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia. Cancer Lett. 2020;472:132–141. doi:https://doi.org/10.1016/j.canlet.2019.11.040.
- Yaghmaie M, Yeung CC. Molecular mechanisms of resistance to tyrosine kinase inhibitors. Curr Hematol Malig Rep. 2019;14:395–404. doi:https://doi.org/10.1007/s11899-019-00543-7.
- Martiny-Baron G, Kazanietz MG, Mischak H, et al. Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976. J Biol Chem. 1993;268:9194–9197.
- Jia XZ, Yang SY, Zhou J, et al. Inhibition of CHK1 kinase by Gö6976 converts 8-chloro-adenosine-induced G2/M arrest into S arrest in human myelocytic leukemia K562 cells. Biochem Pharmacol. 2009;77:770–780. doi:https://doi.org/10.1016/j.bcp.2008.11.008.
- Bokhari SM, Zhou L, Karasek MA, et al. Regulation of skin microvasculature angiogenesis, cell migration, and permeability by a specific inhibitor of PKCalpha. J Invest Dermatol. 2006;126:460–467. doi:https://doi.org/10.1038/sj.jid.5700071.